GenomeWeb: Paradigm4 Moves Into Single-Cell Data, Helps Pharma Address COVID-19

Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk

Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns